Search research articles
Contact Us
Filters
Showing results (51-60 of 260) with videos related to
Page
of 26
Sort By:
Expert Review of Anticancer Therapy
|
October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancer
Timothy A Yap, Carmel J Pezaro, Johann S de Bono
Current Opinion in Oncology
|
July 5, 2022
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations
Natalie Y L Ngoi, Shannon N Westin, Timothy A Yap
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2009
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective
Shahneen K Sandhu, Timothy A Yap, Johann S de Bono
Current Drug Targets
|
July 23, 2011
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment
Shahneen K Sandhu, Timothy A Yap, Johann S de Bono
Nature Reviews. Clinical Oncology
|
August 10, 2011
The changing therapeutic landscape of castration-resistant prostate cancer
Timothy A Yap, Andrea Zivi, Aurelius Omlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development
Timothy A Yap, Udai Banerji, Johann S de Bono, et al.
Cancer Discovery
|
December 23, 2016
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, et al.
British Journal of Cancer
|
July 10, 2023
PARP inhibitors: enhancing efficacy through rational combinations
Deepak Bhamidipati, Jaime I Haro-Silerio, Timothy A Yap, et al.
Frontiers in Medicine
|
April 27, 2017
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Raghav Sundar, Maxime Chénard-Poirier, Dearbhaile Catherine Collins, et al.
British Journal of Cancer
|
January 7, 2015
Combining targeted therapeutics in the era of precision medicine
D Papadatos-Pastos, M J De Miguel Luken, Timothy A Yap
Page
of 26
Search research articles
Search
Showing results (51-60 of 260) with videos related to
Sort By:
Page
of 26
Expert Review of Anticancer Therapy
|
October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancer
Timothy A Yap, Carmel J Pezaro, Johann S de Bono
Current Opinion in Oncology
|
July 5, 2022
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations
Natalie Y L Ngoi, Shannon N Westin, Timothy A Yap
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2009
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective
Shahneen K Sandhu, Timothy A Yap, Johann S de Bono
Current Drug Targets
|
July 23, 2011
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment
Shahneen K Sandhu, Timothy A Yap, Johann S de Bono
Nature Reviews. Clinical Oncology
|
August 10, 2011
The changing therapeutic landscape of castration-resistant prostate cancer
Timothy A Yap, Andrea Zivi, Aurelius Omlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development
Timothy A Yap, Udai Banerji, Johann S de Bono, et al.
Cancer Discovery
|
December 23, 2016
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, et al.
British Journal of Cancer
|
July 10, 2023
PARP inhibitors: enhancing efficacy through rational combinations
Deepak Bhamidipati, Jaime I Haro-Silerio, Timothy A Yap, et al.
Frontiers in Medicine
|
April 27, 2017
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Raghav Sundar, Maxime Chénard-Poirier, Dearbhaile Catherine Collins, et al.
British Journal of Cancer
|
January 7, 2015
Combining targeted therapeutics in the era of precision medicine
D Papadatos-Pastos, M J De Miguel Luken, Timothy A Yap
Page
of 26